Join
Live feed
·
PRReleasevia Quantisnow
Nurix Therapeutics Inc. logo

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

ByQuantisnow·Wall Street's wire, on your screen.
NRIX· Nurix Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRIX (Nurix Therapeutics Inc.) and more on Quantisnow.